Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2024-05-21 Earnings Release
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
Earnings Release Classification · 95% confidence The document is explicitly titled "*PRESS RELEASE*" and details operational progress, strategic updates, clinical trial modifications (Phase 3 pivotal trial in head and neck cancer), FDA feedback ("Study May Proceed" letter), and pipeline updates. This content structure—announcing key operational and clinical milestones outside of a formal periodic financial filing (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses heavily on strategic direction and clinical progress rather than just summarizing quarterly numbers, it aligns best with an Earnings Release (ER) which often includes these strategic highlights, or potentially an Investor Presentation (IP) if it were structured as slides. However, the format is a standard press release announcing results and strategy updates. Given the focus on 'progress' and 'updates' following a period of activity, ER is the most appropriate fit among the choices, as it serves as the primary vehicle for communicating recent operational achievements and strategic shifts to the market. It is not a full financial report (10-K/IR), a transcript (CT), or a formal proxy/governance document. H2 2026
2024-05-21 English
Nanobiotix annonce des avancees de la collaboration globale de developpement autour de NBTXR3 refletant son pipeline robuste et son approche de croissance sur le long terme
Earnings Release Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and dated May 21, 2024. It details strategic updates, collaboration advancements regarding the product NBTXR3, clinical trial progress (Phase 3, Phase 2, Phase 1), regulatory milestones (FDA IND acceptance), and pipeline outlook. This content structure—a formal announcement summarizing recent operational and strategic developments, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses heavily on operational progress, clinical milestones, and strategic alignment rather than just preliminary financial figures (which would suggest ER), and it is not a full report (like 10-K or IR), it fits best as a general corporate announcement. Given the options, it is a high-level update on business strategy and clinical progress. While it contains elements that might be in an Investor Presentation (IP), the format is a press release announcing updates, making it closest to an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were less detailed. However, the detailed nature of the updates on strategy and pipeline progression strongly suggests it is intended for investors and analysts, fitting the scope of an Earnings Release (ER) or a detailed Investor Presentation (IP). Given the length and detail, and the fact that it is a press release announcing significant operational news, ER is a strong candidate, but IP covers detailed pipeline/strategy updates well. Since it is a press release announcing strategic and operational progress, and not explicitly a presentation deck, I will classify it as an Earnings Release (ER) as these often serve as the primary vehicle for such comprehensive updates outside of formal financial reports. If it were purely a presentation deck, IP would be chosen. Since it is a press release detailing business strategy and clinical progress, ER is the most appropriate fit among the choices for a major corporate update. FY 2024
2024-05-21 French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of April 30, 2024. This type of regular disclosure regarding the capital structure and voting rights is a specific regulatory requirement. While it is a regulatory announcement, it is not a general 'RNS' or a report like 10-K or IR. It specifically relates to the composition of the share capital, which aligns closely with notifications about share changes or major holdings, but the most precise fit among the provided options for a monthly capital structure update, especially one that mentions the total number of shares and voting rights, is often categorized under filings related to share capital changes or major ownership notifications. However, given the options, this is a mandatory periodic disclosure about the share base. It is not a Director's Dealing (DIRS), nor a Major Shareholding Notification (MRQ) which usually reports *changes* crossing a threshold, but rather a comprehensive monthly update on the total count. Since it is a mandatory, periodic disclosure of share capital structure, it is best classified as a specific type of regulatory filing. If we look at the definitions, 'SHA' is for Share Issue/Capital Change, which is close, but this is a reporting requirement, not necessarily an action. 'MRQ' is for Major Shareholding Notification, which is also close as it deals with ownership structure. Given the context of mandatory monthly reporting on the total number of shares and voting rights, this is a standard regulatory disclosure. Since there isn't a perfect 'Capital Structure Report' code, and it deals with the total share count, it is most analogous to a notification about the capital base. In many contexts, these monthly reports are filed under general regulatory announcements or specific share capital change disclosures. Given the options, and the focus on the total number of shares and voting rights, it is a specific type of capital structure disclosure. If we must choose the closest fit: it is a mandatory disclosure about the share base. It is not a dividend (DIV), financing (CAP), or insider trade (DIRS). It is a periodic regulatory update. Since it is a formal, periodic disclosure mandated by regulators, and it is not a full financial report, it falls under general regulatory announcements or specific capital structure updates. 'SHA' (Share Issue/Capital Change) is the closest thematic fit for a document detailing the total share count, even if it's a reporting requirement rather than an active change announcement. However, if we consider the nature of the disclosure (periodic update on total shares/votes), it is a very specific type of regulatory filing. Given the options, and the fact that it is a formal, periodic regulatory filing that doesn't fit the other specific categories (like ER, IR, 10-K), 'RNS' (Regulatory Filings - fallback) is a safe choice, but let's re-evaluate 'SHA'. Since the document explicitly states the total number of shares and voting rights, it is fundamentally about the capital structure. I will classify it as 'SHA' as it directly reports on the components of the share capital, which is the subject of that category, even if it's a reporting event rather than an issuance event. The document is short and formal, but it is the report itself, not an announcement of a report. Confidence is high due to the explicit title and content.
2024-05-16 French
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY" and explicitly references French Commercial Code articles (L.233-8 II) and the French Financial Markets Authority (AMF) regulations. It provides a table detailing the 'Number of Shares Outstanding' and 'Total number of voting rights' as of a specific date (April 30, 2024). This type of regular disclosure regarding the total share capital and voting rights is a mandatory regulatory filing in many jurisdictions, often published monthly or quarterly. While it is a regulatory announcement, it specifically deals with the capital structure and voting rights, which is a distinct category from general regulatory filings (RNS) or major shareholding changes (MRQ, which usually reports *who* crossed a threshold). However, none of the provided codes perfectly match a 'Monthly Voting Rights Disclosure'. Given the options, this document reports on the company's capital structure and share count, which is closely related to financing/capital updates (CAP) or general regulatory disclosures (RNS). Since it is a specific, recurring regulatory disclosure about the share base, and not a change in ownership by an external party (MRQ) or a general announcement (RNS), it fits best under the general category of capital structure updates or regulatory filings. Since it is a formal, required disclosure of the capital base, and not a dividend announcement (DIV) or share repurchase (POS), the most appropriate fit among the specific options is difficult. Let's re-evaluate the definitions. It is not a 10-K, AR, ER, or IR. It is not a management change (MANG) or director dealing (DIRS). It is a formal regulatory disclosure about the number of shares. This is often categorized under general regulatory filings (RNS) or sometimes under capital structure updates (CAP). Given the explicit reference to regulatory requirements and the nature of the data (total shares/rights), RNS (Regulatory Filings - fallback) is a safe classification, but let's check if it aligns better with CAP (Capital/Financing Update). Since it is a disclosure *about* the capital base, CAP is plausible, but RNS is the standard fallback for mandatory, non-financial-result disclosures. Since the document is a formal regulatory disclosure about the total capital base, and RNS is the general regulatory filing fallback, I will select RNS. However, if we consider the content is purely about the share count, it is very close to SHA (Share Issue/Capital Change), but SHA usually implies an *action* (issue/split), whereas this is a *report* on the current state. Therefore, RNS is the most appropriate fallback for this specific regulatory report.
2024-05-16 English
NANOBIOTIX publiera ses résultats financiers et opérationnels du premier trimestre 2024 le 22 mai 2024
Earnings Release Classification · 98% confidence The document is a press release dated May 15, 2024, announcing two key future events: 1) The publication of the First Quarter 2024 financial and operational results on May 22, 2024, followed by a conference call. 2) The Annual General Meeting (AGM) scheduled for May 28, 2024. Since the document's primary purpose is to announce the upcoming release of financial results (Q1 2024) and provide details for the associated conference call, it strongly aligns with the definition of an Earnings Release (ER). Although it also mentions the AGM, the immediate focus is on the quarterly financial reporting event. It is not the actual financial report (IR) or the presentation itself (IP), but the announcement of the release date and call details. Therefore, ER is the most appropriate classification for this announcement. Q1 2024
2024-05-15 French
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
Earnings Release Classification · 98% confidence The document is a press release announcing that the company will report its financial and operational results for the first quarter of 2024 on a future date (May 22, 2024). It also mentions details for the associated conference call and webcast. This structure—announcing the upcoming release of periodic financial results—is characteristic of an Earnings Release (ER). Although it mentions the upcoming AGM, the primary focus and immediate news item is the Q1 financial update announcement. Since the document is an announcement *about* the upcoming results, and not the results themselves, ER is the most appropriate classification, as it precedes the actual Earnings Release document. Q1 2024
2024-05-15 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.